A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells

[1] Bohlen H(1993)Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 × CD19 bispecific antibodies in combination with bivalent CD28 antibodies Blood 82 1803-1812

[2] Hopff T(1996)Targeting of peripheral blood T lymphocytes Springer Semin Immunopathol 18 211-226

[3] Manzke O(1995)Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody J Natl Cancer Inst 87 1463-1469

[4] Engert A(1999)Costimulatory regulation of T-cell function Curr Opin Cell Biol 11 203-210

[5] Kube D(1999)Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature Cancer Res 59 3192-3198

[6] Wickramanayake PD(2000)Treatment of human B cell lymphoma xenografts with a CD3 × CD19 diabody and T cells J Immunol 165 888-895

[7] Diehl V(2003)T-cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B-cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct J Immunol 170 4397-4402

[8] Tesch H(2006)A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer Prostate 66 1359-1370

[9] Bolhuis RL(2004)Efficient inhibition of multidrug-resistant human tumors with a recombinant bispecific anti-P-glycoprotein x anti-CD3 diabody Leukemia 18 513-520

[10] Hoogenboom HR(2004)Tumor target prostate-specific membrane antigen (PSMA) and its regulation in prostate cancer J Cell Biochem 91 528-539

[1] Bohlen H(1993)Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 × CD19 bispecific antibodies in combination with bivalent CD28 antibodies Blood 82 1803-1812

[2] Hopff T(1996)Targeting of peripheral blood T lymphocytes Springer Semin Immunopathol 18 211-226

[3] Manzke O(1995)Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody J Natl Cancer Inst 87 1463-1469

[4] Engert A(1999)Costimulatory regulation of T-cell function Curr Opin Cell Biol 11 203-210

[5] Kube D(1999)Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature Cancer Res 59 3192-3198

[6] Wickramanayake PD(2000)Treatment of human B cell lymphoma xenografts with a CD3 × CD19 diabody and T cells J Immunol 165 888-895

[7] Diehl V(2003)T-cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B-cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct J Immunol 170 4397-4402

[8] Tesch H(2006)A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer Prostate 66 1359-1370

[9] Bolhuis RL(2004)Efficient inhibition of multidrug-resistant human tumors with a recombinant bispecific anti-P-glycoprotein x anti-CD3 diabody Leukemia 18 513-520

[10] Hoogenboom HR(2004)Tumor target prostate-specific membrane antigen (PSMA) and its regulation in prostate cancer J Cell Biochem 91 528-539